Scandion Oncology

Overcoming cancer drug resistance

The board of directors hereby gives notice of the annual general meeting in:   Scandion Oncology A/SCVR no. 38613391(the "Company")  to be held on Thursday, March 27, 2025, at 14.00 (CET), at the Company's address, Fruebjergvej 3, 2100 Copenhagen, Denmark.   With the following agenda:   1.   Election of chairman of the meeting   2.   Report from the board of directors on the Company's business in the past year   3.   Presentation of the audited annual report for approval   4.   Proposal of notice of discharge to the board of directors and the executive board   5.   Decision on appropriation of profit or loss as recorded in the approved annual report   6.   Proposal to enter into voluntary solvent liquidation   7.   Proposal to elect a liquidator   8.   Proposal to approve the board of directors' fee for Q1 2025   9.   Election of members of the board of directors   10. Election of auditor   11. Any other business   More details to each of the agenda items can be found in schedule 1: Full wording of the proposals on the agenda.   The annual general meeting will be conducted in English.   Proposal to enter into voluntary solvent liquidation (agenda item 6) On 26 February 2025, the Company reported that the Company had unfortunately so far been unsuccessful in attracting a partner and/or securing funding to progress the Company's programs.The board of directors therefore resolved on a 12 March deadline for the Company to secure a partner or another source of funding. If no partner or other source of funding had been secured by 12 March 2025, the board of directors would propose and recommend to the annual general meeting that the Company enters into voluntary solvent liquidation. Unfortunately, no partner or other source of funding has been found and with the Company's current cash being insufficient to fund operations further than into 2H 2025, the board of directors is therefore proposing that the Company enters into voluntary solvent liquidation (agenda item 6). As reported on 26 February, it is the expectation that the Company's cash reserve will be sufficient to cover the expected liquidation costs and claims from creditors, however, at this time the Company does not expect that there will be liquidation proceeds to be distributed among the Company's shareholders at the end of a liquidation process. If the proposal is approved, the board of directors and executive management will […]

Scandion Oncology today announces the Annual Report 2024 which is available on the company’s website. For further information please contact:Johnny Stilou, CFOPhone: +45 2960 3532E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on March 12, 2025, at 13.05 CET. About Scandion Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Vator Securities is the Company's certified advisor on Nasdaq First North Growth Market. AttachmentsScandion Oncology Annual Report 2024 Scandion Oncology Annual Report 2024